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Background—The Fagerström Test for Nicotine Dependence (FTND), a derivation of the
Fagerström Tolerance Questionnaire, was first published in 1991. The FTND remains one of the
most widely used measures of nicotine dependence for studying genetic and epidemiological risk
factors and the likelihood of smoking cessation. However, it is unclear whether secular trends in
patterns of smoking alter the psychometric properties of the FTND and its interpretation.
Methods—We examined measurement invariance in the lifetime and current FTND scores across
birth cohorts using participants drawn from six study samples (N=13,775).

Author Manuscript

Results—We found significant (p<0.05) measurement non-invariance in means and factor
loadings of most FTND items by birth cohort, but effect sizes, ranging from r2=0.0001 to
r2=0.0035, indicated that less than 0.5% of the model variance was explained by the measurement
non-invariance for each factor loading. To assess its impact, we regressed the lifetime FTND latent
variable on well-established factors associated with nicotine dependence (quitting smoking and the
nicotinic acetylcholine receptor gene [CHRNA5] variant rs16969968, separately), and we
observed that the regression coefficients were unchanged between models with and without
adjustment for measurement non-invariance.
Conclusions—These findings suggest that possible FTND non-invariance that occurs across
study samples of various birth years has a negligible impact on study results.
Keywords
measurement invariance; birth year; nicotine dependence; Fagerström Test for Nicotine
Dependence; tobacco smoking
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1. Introduction

Author Manuscript

Nicotine dependence studies are increasingly combining samples of participants to increase
statistical power and make comparisons across groups of diverse age, race/ethnicity, and sex
(Belsky et al., 2013; Bierut et al., 2007; Fagerstrom and Furberg, 2008; John et al., 2003). In
studies that compare an underlying latent trait, like nicotine dependence, it is assumed that
the instrument is measuring the trait on a consistent scale (i.e., it is invariant, measuring the
trait similarly across groups) (Widaman and Reise, 1997). Measurement non-invariance is a
type of measurement error that can bias study results toward or away from the null
hypothesis, thereby leading to incorrect results in statistical comparisons and increasing the
chances of both Type 1 and Type 2 errors. A non-invariant measure of nicotine dependence
might incorrectly suggest that groups differ in their dependence levels (Schroeder and
Moolchan, 2007) or the relation between dependence and other key variables (e.g.,
estimating the association between nicotine dependence and cessation, in which cessation is
correlated with group membership like age (Johnson et al., 2008)). Measurement invariance
may also obscure true associations, making them appear non-significant. Moreover, if a noninvariant measure is used as an inclusion criterion across groups, it might allow recruitment
of groups that unintentionally differ on trait dependence because the same score may be
differently related across groups to the underlying latent dependence (Robinson et al., 2006).
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The Fagerström Test for Nicotine Dependence (FTND; also called the Fagerström Test for
Cigarette Dependence (Fagerstrom, 2012)) is perhaps the most widely used measure for
studying genetic and epidemiological risk factors of nicotine dependence and likelihood of
smoking cessation (Haddock et al., 1999; Heatherton et al., 1991). It focuses on core
dependence criteria, including heavy use/tolerance and withdrawal (Baker et al., 2012), and
remains an especially strong predictor of smoking cessation (Fagerstrom et al., 2012; Fidler
et al., 2011). Its use across diverse studies with varying participant characteristics makes
measurement invariance a vital psychometric issue to support the accuracy of analytic
findings across a variety of studies.

Author Manuscript

Secular trends in smoking might produce measurement non-invariance in longitudinal
studies and studies that incorporate cross-sectional data collected at different times across
multiple samples if the salience of dependence symptoms were affected across different
birth cohorts. Smoking prevalence was relatively low in the U.S. before 1939 but increased
up until the 1960s, when almost half of adults smoked. The 1964 Surgeon General’s report
(U.S. Surgeon General’s Advisory Committee on Smoking and Health) marked another
turning point, and smoking prevalence has fallen since (Figure S1)1 (U.S. Department of
Health Human Services, 2014). A concomitant evolution in the social stigma and legal
context of smoking have also affected smoking behaviors that are key indicators of
dependence in the FTND (e.g., more difficulty refraining from smoking, fewer cigarettes per
day [CPD] because smoking is forbidden in many public places), potentially making them
more salient indicators of nicotine dependence.
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Our study assessed measurement invariance in FTND by birth cohort and quantified the
magnitude of significant effects. This address whether FTND scores have the same meaning
when collected in different individuals studied at different times and whether results of
studies using FTND across multiple birth cohorts are likely to be biased by this
measurement error.

2. Methods
2.1 Study Samples

Author Manuscript

We used five study samples that collected FTND data from 1989 to 2013: African American
Nicotine Dependence (AAND), Collaborative Genetic Study of Nicotine Dependence
(COGEND), Center for Oral Health Research in Appalachia (COHRA1), Chronic
Obstructive Pulmonary Disease Gene (COPDGene®), and University of Wisconsin
Transdisciplinary Tobacco Use Research Center (UW-TTURC). See Supplementary
Material and Table S11 for detailed sample descriptions. All protocols received Institutional
Review Board approval at their respective sites. All study participants provided informed
consent.

1Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
1Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
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2.2 Measures
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2.2.1 Exposure—Birth cohort was categorized into three groups (Figure S1)1 (U.S.
Department of Health Human Services, 2014): (1) those born before 1945, a period of low
but increasing cigarette consumption; (2) those born 1945–1975, the period of highest per
capita cigarette consumption that peaked around the 1964 report (U.S. Surgeon General’s
Advisory Committee on Smoking and Health); and (3) those born after 1975, when cigarette
consumption steadily declined.
2.2.2 Outcomes—The FTND is a six-item questionnaire with scores ranging from 0 (no
dependence) to 10 (highest dependence level). Our study focused on FTND scores based on
habits among current smokers (current FTND) and compared them with results from when
they reported smoking the most (lifetime FTND).

Author Manuscript

To evaluate the impact of any measurement non-invariance, we examined the relationship of
lifetime FTND on quitting smoking. Quitting smoking was defined among lifetime smokers
as either a self-reported status of “quit” or a frequency of 0 cigarettes smoked in the past
month (depending on which measure was available).
Finally, we conducted analyses to evaluate the impact of any measurement non-invariance
on rs16969968, the functional coding single nucleotide polymorphism (SNP) in the nicotinic
acetylcholine receptor gene CHRNA5, that is robustly associated with nicotine dependence
(Hancock et al., In-press). Rs16969968 was either genotyped or imputed with high quality
(IMPUTE2 “info” quality metric = 0.99–1) in each of the five study samples and additively
coded (ranging from 0 to 2 for the number of G alleles carried) for analysis, as previously
described (Hancock et al., 2017a).

Author Manuscript

2.3 Statistical Analyses
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2.3.1 Measurement Invariance—We tested item-level measurement invariance for birth
cohort by using multiple-indicator, multiple-cause (MIMIC) models with a weighted least
squares parameter estimates with standard errors and a mean- and variance-adjusted chisquare test statistic that used a full weight matrix (an estimator appropriate for use with
categorical data) (Johnson et al., 2008; Kline, 2010). MIMIC models are structural equation
models that can examine group-specific effects on item responses relative to a reference
group, without mediation through a latent variable (i.e., nicotine dependence). Figure 1
provides an example of a MIMIC model testing an item-level difference in FTND item 5
(smoke more frequently during the first hours after waking than during the rest of the day)
by birth cohort, with those born <1945 as the reference. Each FTND item was tested this
way. Modeling the direct paths from each birth cohort, adjusting for nicotine dependence
level, results in estimates of response differences attributable to measurement noninvariance. Models including direct paths from each birth cohort to each FTND item were
compared to nested models, where direct paths were fixed to zero using Mplus difftest to
determine the statistical significance of non-invariance (Muthén and Muthén, 1998–2015).
Separate models were run with different reference groups to examine all pairwise
differences (e.g., birth cohorts 2 and 3 vs. 1; birth cohorts 1 and 3 vs. 2). Results for other
reference groups are presented in the Supplementary Material. For significant item-level
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invariance (direct-path parameter estimates with p<0.05 in the final model), eta-squared (r2)
effect sizes were calculated (Ferguson, 1966).
All MIMIC and regression models controlled for study sample and final models included an
adjustment for measurement invariance. Statistical testing was two-tailed with α=0.05. Betas
are reported as standardized parameter estimates. Analyses were conducted using Mplus
version 7 (Muthén and Muthén, 1998–2015).

Author Manuscript

We present results of models that included a control variable for study sample because of
different study enrollment criteria. There was overlap between birth cohort and study (e.g.,
some studies had younger or older participants), and to test whether controlling for study
removed variance related to birth cohort, we conducted sensitivity analyses uncontrolled for
study. Results (not shown) were substantively the same. Additionally, the cohort exposure
group was changed from birth year to birth year plus 10 to mimic age of first tobacco
exposure. Results (not shown) were consistent with the birth cohort findings.
2.3.2 Regression Analyses—Two regression models were tested to assess the impact of
item-level invariance. First, quitting smoking was regressed on the FTND latent variable in
baseline models that did not account for item invariance and compared to adjusted models
that accounted for model invariance (Figure S2)1. Second, a similar procedure was
conducted to evaluate the impact of measurement non-invariance on the association between
FTND and Rs16969968. The regression coefficients were compared between baseline and
adjusted models. All regression analyses, included sex (male or female), race (European
American or African American), and study sample (AAND, COGEND, COHRA1,
COPDGene, or UW-TTURC) as covariates. All statistical testing was two-tailed with p<.05
used to declare statistical significance.

Author Manuscript

3. RESULTS
3.1 Descriptive Statistics
Current FTND analyses included 9,865 participants (Table S1)1. AAND, COGEND, and
COHRA1 had the lowest proportions of participants in the oldest birth cohorts; COPDGene
had the oldest participants, and UW-TTURC had a more normally shaped distribution for the
year of birth.

Author Manuscript

Current FTND scores differed significantly by birth cohort. FTND was highest among those
born 1945–1975 (mean=5.1; Table 1), followed by those born <1945 (mean=4.7), and lowest
among those born >1975 (mean=4.2). Moreover, birth cohort differed significantly for each
FTND item (X2 p<0.05). Response patterns for FTND items varied greatly. For example,
27.1% of those born <1945 reported having their first cigarette within 5 minutes of waking,
compared with 38.8% of those born 1945–1975, and 39.3% of those born >1975.
3.1.1 Measurement Invariance—Table 2 presents the results of baseline and fitted
MIMIC models testing for birth cohort measurement invariance for current FTND models

1Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
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using birth <1945 as the reference. This model demonstrated poor fit (X2= 4364.34 (39), p<.
001) with comparative fit index (CFI)=0.478 and root mean square error of approximation
(RMSEA)=0.108 and a worsening fit with adjustment for FTND measurement noninvariance (X2=4213.75 (20), p<.001, CFI=0.495, and RMSEA=0.123) (Hu and Bentler,
1999). Results evaluating measurement invariance for current FTND using 1945–1975 as a
reference group were largely similar to analyses using <1945 as the reference, including a
low level of measurement non-invariance that accounted for little of the model variance and
did not greatly affect the modelling results when invariance was adjusted for (Table S2)1.

Author Manuscript

Mean latent variable differences in current dependence were examined for both birth cohort
reference groups. Mean dependence among those born <1945 was significantly different
than those born 1945–1975; this difference remained largely unchanged after accounting for
measurement non-invariance (unadjusted β=0.171, p<.001, adjusted β=0.178, p<.001). Birth
cohorts 1945–1975 and <1945 did not differ significantly in mean dependence in both
unadjusted and adjusted models (unadjusted β=0.034, p=0.118, adjusted β=0.039, p=0.149).
Evaluating item-level non-invariance in the model using birth cohort <1945 as the reference,
10 parameters show statistically significant measurement non-invariance. Time to first
cigarette in the morning was the only current FTND item that did not show measurement
non-invariance. The effect sizes for these direct paths ranged from r2=0.0003 to r2=0.0035
indicating that, despite statistical significance, little variance (<0.5%) of the model was
explained by measurement non-invariance. Fewer significant parameters were noted for the
model using birth cohort 1945–1975 as the reference group, and they were of lower
magnitude (Table S2)1. A similar pattern of results was observed for lifetime FTND.

Author Manuscript

3.1.2 Regression Analyses—Chi-square tests for differences in quitting smoking by
birth cohort indicated that those in the oldest cohort were the most likely to have quit (Table
S3)1. For example, among participants with lifetime FTND, 49.2 % of those born before
1945 had quit, compared with 22.4% of those born between 1945 and 1975 and 15.5% of
those born after 1975. To determine whether these differences were due to measurement
non-invariance rather than other causes, regression models were created with and without
accounting for non-invariance (Table 3). In baseline models for the birth cohort (using birth
cohort 1945–1975), higher lifetime FTND scores were associated with less quitting, as
expected (odds ratio =0.48, 95% confidence interval [CI] =0.40–0.44, p<.001). After
adjusting for measurement non-invariance, the odds ratio and 95% CI estimates did not
change.

Author Manuscript

Similar findings were observed when examining the association between rs16969968 and
lifetime FTND. Consistent with prior studies (Hancock et al., In-press), carrying the
rs16969968-G protective allele was associated with a lower lifetime FTND score (β= −0.09
(0.02), 95% CI= −0.16–−0.07, p<.001). Moreover, as expected given the low level of
measurement non-invariance detected in MIMIC modes, the association between

1Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
1Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
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rs16969968 and FTND did not change when controlling for the measurement noninvariance.

4. Discussion

Author Manuscript

Measurement invariance is important when attempting to compare groups on underlying
latent characteristics like nicotine dependence. Measurement non-invariance can lead to
incorrect conclusions about the differences across groups, obscuring differences that exist or
creating differences due to measurement non-invariance rather than actual differences, as
well as add heterogeneity to analyses that combine cohorts from different eras (e.g., metaanalytic genome-wide association studies). For the first time, we assessed FTND
measurement invariance by birth cohort using cross-sectional studies that collectively
comprise individuals born from 1926 through 1998. The pattern of responses to current
FTND items has changed over time, including higher CPD and lower tendency to smoke
when sick in the oldest respondents (birth cohort <1945). Thus, verifying measurement
invariance across different birth cohorts is important for instilling confidence in study results
that combine or compare FTND across different age groups.

Author Manuscript

Our findings revealed some statistically significant non-invariance for FTND items,
including CPD, which is often collected and analyzed on its own. However, the effect sizes
of the item-level non-invariance accounted for <0.5% of the model variance, indicating that
while it is advisable to control for year of birth in analyses using FTND, failure to do so
should not greatly alter analytic results, which was confirmed through analyses examining
the impact of adjusting for the measurement non-invariance in regression models. In models
evaluating the association between FTND and quitting smoking, the odds ratios, and 95% CI
estimates were unchanged when controlling for the measurement non-invariance. Moreover,
even in genetic analyses where the effects of SNPs often account for small portions of the
variance in nicotine dependence (altogether <15%; Hartz, et al., 2017), the measurement
non-invariance is likely to have little demonstrable effect, as evidenced by β and 95% CI
estimates of the FTND and rs16969968 association being unchanged when controlling for
the measurement non-invariance. Therefore, although smoking patterns have changed over
time, these changes have not affected the ability of the FTND to assess nicotine dependence.

Author Manuscript

This study has limitations. First, some study samples had small coverage over some birth
cohorts (e.g., AAND had no one born <1945). Due to differences in recruitment criteria, we
controlled for study sample in all models, but the overlap in sample and coverage may have
led to over controlling for invariance with the addition of study sample in the model.
However, no single study sample provided all data for a birth cohort, and sensitivity analyses
indicated similar results when controlling versus not controlling for the study sample. A
related concern involved the different eligibility criteria for the included studies, but
controlling for sample should have helped to control this variability. Notably, the overall
model fit indices revealed poor fit in baseline and final MIMIC models. While this suggests
substantial variation in the ability of the model to reproduce the overall data, there was no
notable difference in fit between models that did and did not adjust for measurement noninvariance. This suggests that model fit was driven by variation in the data (e.g., current
FTND had poorer model fit than lifetime FTND, studies differed in their inclusion criteria)

Drug Alcohol Depend. Author manuscript; available in PMC 2019 April 01.

Glasheen et al.

Page 8

Author Manuscript

and not by measurement non-invariance. Finally, variation associated with birth cohort could
be due to the participants’ age at assessment. However, this concern is reduced by broad
variation in the median birth year, even among studies with similar recruitment periods
(Table S1)1. Post hoc analyses evaluating model fit while controlling for study sample, sex,
and race further support that the variability across studies may be a primary driver of poor
fit, as model fit improved modestly (RMSEA = 0.090 vs. 0.108 and CFI= 0.595 vs. 0.478 for
the unadjusted vs. covariate-adjusted models). Moreover, model fit was good for regression
models that included latent variable modeling of FTND and covariates.

Author Manuscript

These findings build upon prior analyses across important demographic groups. Schroeder
and Moolchan (2007) found some measurement non-invariance in FTND across European
and African ancestry participants, which we confirmed but further found the FTND to have
only minor measurement non-invariance by sex and race (Johnson et al., 2008). Altogether,
the prior and current findings increase confidence for researchers concluding comparisons
made across birth cohorts using the FTND, as manifest scores have similar relations with an
underlying dependence dimension regardless of birth cohort. Likewise, meta-analyses
incorporating results from different birth cohorts are unlikely biased by non-invariance–
induced heterogeneity. The FTND, therefore, provides a robust basis for comparing nicotine
dependence across populations and informing public health research.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
•

The six-item Fagerström Test for Nicotine Dependence (FTND) is widely
used.

•

Secular trends in smoking may have altered psychometric properties of the
FTND.

•

We found item-level invariance by birth year, but effect sizes were very small.

•

The utility of the FTND is reinforced, and adjusting for birth year is ideal.

•

Not adjusting for birth year should have negligible impact on study results.

Author Manuscript
Author Manuscript
Author Manuscript
Drug Alcohol Depend. Author manuscript; available in PMC 2019 April 01.

Glasheen et al.

Page 12

Author Manuscript
Author Manuscript

FIGURE 1.

Example MIMIC Model Testing for Item-level Differences in FTND Item 5 (Smoke More
Frequently During the First Hours After Waking than During the Rest of the Day) by Birth
Cohort Using <1945 as the Reference Group.
Note: Study sample is dummy coded into indicator variables but has been simplified in this
figure for illustrative purposes.
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TABLE 1

Author Manuscript

CURRENT FAGERSTRÖM TEST FOR NICOTINE DEPENDENCE (FTND) ITEM DISTRIBUTION BY
BIRTH COHORT
<1945

1945–1975

>1975

N=806

N=7794

N=1265

4.7 (2.2)

5.1 (2.2)

4.2 (2.1)

60+ minutes

16.0

9.0

11.8

31–60 minutes

15.9

14.6

16.3

5–30 minutes

41.0

37.6

32.6

<5 minutes

27.1

38.8

39.3

No

80.6

62.6

65.3

Yes

19.4

37.4

34.7

Any other

36.8

35.1

39.4

First one of the morning

63.2

64.9

60.6

<=10

12.9

22.1

56.0

11–20

52.6

49.8

35.5

21–30

18.4

17.8

7.3

30+

16.1

10.3

1.2

No

57.6

51.7

59.6

Yes

42.4

48.3

40.4

No

75.2

55.0

61.6

Yes

24.8

45.0

38.4

Mean FTND (s.d.) a,b,c
Time to first cigarette (FTND1) a,b

Difficult to refrain (FTND2) a,b

Author Manuscript

Cigarette most hate to give up (FTND3) c

Cigarettes smoked per day (FTND4) a,b,c

Smoke more in the morning (FTND5) a,c

Author Manuscript

Smoke while sick (FTND6) a,b,c

a

Difference between first birth cohort and second birth cohort are significant at p<0.05

b

Difference between first birth cohort and third birth cohort are significant at p<0.05

c

Difference between second birth cohort and third birth cohort are significant at p<0.05

Author Manuscript
Drug Alcohol Depend. Author manuscript; available in PMC 2019 April 01.

Glasheen et al.

Page 14

TABLE 2

Author Manuscript

Baseline and Final MIMIC Model Estimates of Current Fagerström Test for Nicotine Dependence (FTND):
Testing Measurement Invariance Across Birth Cohort Using <1945 as the Reference Group

Author Manuscript

β, Baseline Model

β, Final Model

FTND1

0.680***

0.680***

FTND2

0.574***

0.560***

FTND3

0.415***

0.419***

FTND4

0.454***

0.466***

FTND5

0.463***

0.466***

FTND6

0.598***

0.583***

Cohort: <1945

Reference

Reference

Cohort: 1945–1975

0.171***

0.178***

0.034

0.039

Parameter

Effect Size r2

Standardized loadings

Nicotine dependence on cohort

Cohort: >1975
Direct effects
FTND1
Cohort: < 1945

Reference

Cohort: 1945–1975

n.s.

Cohort: >1975

n.s.

FTND2
Cohort: <1945

Reference

Author Manuscript

Cohort: 1945–1975

0.100***

0.0015

Cohort: >1975

0.126***

0.0024

FTND3
Cohort: <1945

Reference

Cohort: 1945–1975

−0.041*

0.0003

Cohort: >1975

−0.061**

0.0007

FTND4
Cohort: <1945

Reference

Cohort: 1945–1975

−0.118***

0.0022

Cohort: >1975

−0.150***

0.0035

FTND5
Cohort: <1945

Reference

Author Manuscript

Cohort: 1945–1975

−0.046*

0.0004

Cohort: >1975

−0.061**

0.0007

FTND6
Cohort: <1945

Reference

Cohort: 1945–1975

0.103***

0.0016

Cohort: >1975

0.111***

0.0019
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Parameter

β, Baseline Model

β, Final Model

Effect Size r2

Model fit summary

Author Manuscript

Chi-Square (d.f.), p- value

4364.34 (39), p<.001

4213.75 (29), p<.001

CFI

0.478

0.495

RMSEA

0.108

0.123

Notes: FTND1: Time to first cigarette; FTND2: Difficult to refrain in places; FTND3 Cigarette most hate to give up; FTND4: Cigarettes Per Day;
FTND5: Smoke more in the morning; FTND6: Smoke while sick. n.s., not significant. The baseline model is unadjusted for measurement
invariance. The final model adjusts for significant measurement invariance. All models also controlled for study sample.

*

p<0.05,

**
p<0.01,
***
p<0.001.

Author Manuscript
Author Manuscript
Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
871.045 (48)***
0.060
0.954

CFI
RMSEA

N/A

N/A

N/A

0.02 (0.04)

Cohort >1975
Chi-Square (d.f.)

N/A

0.01 (0.04)

Cohort <1945

N/A

N/A

−0.09 (0.02)***

FTND

N/A

0.062

RMSEA

N/A

1002.87 (48)***

Chi-Square (d.f.)
N/A

0.67

−0.42 (0.05)***

Cohort >1975

0.960

0.74

−0.30 (0.05)***

Cohort <1945

CFI

0.48

OR

−0.74 (0.01)***

β (S.E.)

FTND

Parameter

N/A

N/A

N/A

−0.11–0.07

−0.07–0.11

−0.16–0.07

N/A

N/A

N/A

0.23–0.40

0.34–0.56

0.40–0.44

95% CI
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p<0.001.

The baseline model is unadjusted for measurement invariance.

1

***

p<0.01,

**

p<0.05,

*

β (S.E.)

0.955

0.062

849.23 (44)***

0.02 (0.04)

0.01 (0.04)

−0.09 (0.02)***

0.064

0.961

978.89 (44)***

−0.42 (0.05)***

−0.31 (0.05)***

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

0.67

0.73

0.48

OR

N/A

N/A

N/A

−0.30–0.19

−0.20–0.26

−0.16–0.07

N/A

N/A

N/A

0.23–0.40

0.34–0.56

0.40–0.44

95% CI

Invariance Adjusted Model

−0.74 (0.01)***

N/A, not applicable. All models controlled for study sample, sex, and race. Birth cohort 1945–1975 was used as reference.

Additive rs16969968 genotype (Linear Model)

Quit Smoking (Logistic Model)

Model

Baseline1 Model

Regression Models for Quitting Cigarette Smoking and rs16969968 Regressed on Lifetime FTND and Birth Cohort Before and After Adjusting for
Measurement Non-Invariance.
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